ImmunoGen (IMGN)
ImmunoGen Cash and ST Investments: 175.58M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
IMGN Cash and ST Investments Rankings
| Overall | 65th percentile | 1523 of 4371 |
| Sector | 75th percentile | 126 of 504 in Healthcare |
| Industry | 76th percentile | 37 of 160 in Biotechnology |
IMGN Cash and ST Investments Range, Past 5 Years
| Minimum | 41.24M | Mar 2008 |
| Maximum | 192.22M | Jun 2011 |
| Average | 89.23M |
About Cash and Short Term Investments
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities
Learn More
You may also be interested in these IMGN related companies
IMGN News
$IMGN http://stks.co/3yyo Trading Ideas for Fri May 25: $IMGN $BBBY $FL http://stks.co/3yyp
about 6 days ago by TraderHR
about 6 days ago by TraderHR
$IMGN http://stks.co/3vUP could break out of multi-month consolidation, watch for a move above $15 http://stks.co/3vUQ
about 9 days ago by TraderHR
about 9 days ago by TraderHR
RT @adamfeuerstein Orbimed Advisors top 5 new buys in Q1: $ONXX $CCXI $IMGN $NBIX $ARRY, per 13F #biotech
about 14 days ago by WolfsBiotechs
about 14 days ago by WolfsBiotechs
ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
May 08, 6:30AM Business Wire
May 08, 6:30AM Business Wire
News related to $IMGN, currently 0.0% since open: 'ImmunoGen fiscal 3Q loss widens as expenses rise' http://stks.co/3YQ1
about 33 days ago by TradeBot
about 33 days ago by TradeBot
Listen to $IMGN Q3 2012 earnings call - live at 08:00 AM, ondemand after - http://stks.co/3Y1e
about 33 days ago by earningscast
about 33 days ago by earningscast
ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2012 Financial Results and Provides Quarterly Update
Apr 27, 6:30AM Business Wire
Apr 27, 6:30AM Business Wire
ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2012 Financial Results
Apr 18, 4:15PM Business Wire
Apr 18, 4:15PM Business Wire
ImmunoGen, Inc. Announces the IND Is Now Active for Its Folate-Receptor Targeting Anticancer Compound, IMGN853
Apr 17, 6:30AM Business Wire
Apr 17, 6:30AM Business Wire
ImmunoGen, Inc. Initiates Phase I Trial in Non-Hodgkin’s Lymphoma with Its Novel IMGN529 Anticancer Compound
Apr 17, 6:15AM Business Wire
Apr 17, 6:15AM Business Wire
ImmunoGen (IMGN) Pops Higher Following Positive T-DM1 Phase III Results
Mar 30, 8:24AM Street Insider
Mar 30, 8:24AM Street Insider
ImmunoGen (IMGN) Reports Positive Top-Line Results from T-DM1 EMILIA Phase III
Mar 30, 8:22AM Street Insider
Mar 30, 8:22AM Street Insider
ImmunoGen Announces Initiation of Phase II Evaluation of Its IMGN901 Product Candidate
Mar 30, 6:42AM Benzinga
Mar 30, 6:42AM Benzinga
ImmunoGen, Inc. Announces Initiation of Phase II Evaluation of Its IMGN901 Product Candidate
Mar 30, 6:00AM Business Wire
Mar 30, 6:00AM Business Wire
ImmunoGen, Inc. Announces Positive Results in Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial
Mar 30, 1:01AM Business Wire
Mar 30, 1:01AM Business Wire
$IMGN forms bullish "Continuation Diamond" chart pattern. http://stks.co/2tSZ
about 76 days ago by RecogniaEvents
about 76 days ago by RecogniaEvents
ImmunoGen, Inc. Announces Webcast of Presentation at the Cowen 32nd Annual Health Care Conference
Mar 02, 3:00PM Business Wire
Mar 02, 3:00PM Business Wire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IMGN | 14.32 | -0.15 | -1.04% | 1.111B |
| IMC | 15.21 | -0.07 | -0.47% | |
| IMAX | 21.42 | -0.55 | -2.50% | 1.435B |
| IM | 18.02 | -0.07 | -0.39% | 2.715B |
| ILMN | 44.20 | +0.00 | +0.00% | 5.448B |
| ILF | 40.15 | -0.64 | -1.57% | |
| IL | 4.07 | -0.14 | -3.33% | 230.50M |
| MCD | 90.01 | -0.89 | -0.98% | 92.59B |
| MCBF | 1.15 | -0.09 | -7.26% | 2.358M |
| MCBC | 3.278 | +0.03 | +0.85% | 88.76M |
